Cargando…
IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis
Human obesity is associated with decreased circulating adiponectin and elevated leptin levels. In vitro experiments and studies in high fat diet (HFD)-fed mice suggest that interleukin-6 (IL-6) may regulate adiponectin and leptin release from white adipose tissue (WAT). Herein, we aimed to investiga...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911215/ https://www.ncbi.nlm.nih.gov/pubmed/33572989 http://dx.doi.org/10.3390/metabo11020079 |
_version_ | 1783656289024344064 |
---|---|
author | Wueest, Stephan Seelig, Eleonora Timper, Katharina Lyngbaek, Mark P. Karstoft, Kristian Donath, Marc Y. Ellingsgaard, Helga Konrad, Daniel |
author_facet | Wueest, Stephan Seelig, Eleonora Timper, Katharina Lyngbaek, Mark P. Karstoft, Kristian Donath, Marc Y. Ellingsgaard, Helga Konrad, Daniel |
author_sort | Wueest, Stephan |
collection | PubMed |
description | Human obesity is associated with decreased circulating adiponectin and elevated leptin levels. In vitro experiments and studies in high fat diet (HFD)-fed mice suggest that interleukin-6 (IL-6) may regulate adiponectin and leptin release from white adipose tissue (WAT). Herein, we aimed to investigate whether IL-6 receptor blockade affects the levels of circulating adiponectin and leptin in obese human individuals. To this end, serum samples collected during a multicenter, double-blind clinical trial were analyzed. In the latter study, obese human subjects with or without type 2 diabetes were randomly assigned to recurrent placebo or intravenous tocilizumab (an IL-6 receptor antibody) administration during a 12-week exercise training intervention. Twelve weeks of tocilizumab administration (in combination with exercise training) trend wise enhanced the decrease in circulating leptin levels (−2.7 ± 8.2% in the placebo vs. −20.6 ± 5.6% in tocilizumab, p = 0.08) and significantly enhanced the increase in circulating adiponectin (3.4 ± 3.7% in the placebo vs. 27.0 ± 6.6% in tocilizumab, p = 0.01). In addition, circulating adiponectin levels were negatively correlated with the homeostatic model assessment of insulin resistance (HOMA-IR), indicating that increased adiponectin levels positively affect insulin sensitivity in people with obesity. In conclusion, IL-6 receptor blockade increases circulating adiponectin levels in people with obesity. |
format | Online Article Text |
id | pubmed-7911215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79112152021-02-28 IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis Wueest, Stephan Seelig, Eleonora Timper, Katharina Lyngbaek, Mark P. Karstoft, Kristian Donath, Marc Y. Ellingsgaard, Helga Konrad, Daniel Metabolites Brief Report Human obesity is associated with decreased circulating adiponectin and elevated leptin levels. In vitro experiments and studies in high fat diet (HFD)-fed mice suggest that interleukin-6 (IL-6) may regulate adiponectin and leptin release from white adipose tissue (WAT). Herein, we aimed to investigate whether IL-6 receptor blockade affects the levels of circulating adiponectin and leptin in obese human individuals. To this end, serum samples collected during a multicenter, double-blind clinical trial were analyzed. In the latter study, obese human subjects with or without type 2 diabetes were randomly assigned to recurrent placebo or intravenous tocilizumab (an IL-6 receptor antibody) administration during a 12-week exercise training intervention. Twelve weeks of tocilizumab administration (in combination with exercise training) trend wise enhanced the decrease in circulating leptin levels (−2.7 ± 8.2% in the placebo vs. −20.6 ± 5.6% in tocilizumab, p = 0.08) and significantly enhanced the increase in circulating adiponectin (3.4 ± 3.7% in the placebo vs. 27.0 ± 6.6% in tocilizumab, p = 0.01). In addition, circulating adiponectin levels were negatively correlated with the homeostatic model assessment of insulin resistance (HOMA-IR), indicating that increased adiponectin levels positively affect insulin sensitivity in people with obesity. In conclusion, IL-6 receptor blockade increases circulating adiponectin levels in people with obesity. MDPI 2021-01-29 /pmc/articles/PMC7911215/ /pubmed/33572989 http://dx.doi.org/10.3390/metabo11020079 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Wueest, Stephan Seelig, Eleonora Timper, Katharina Lyngbaek, Mark P. Karstoft, Kristian Donath, Marc Y. Ellingsgaard, Helga Konrad, Daniel IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis |
title | IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis |
title_full | IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis |
title_fullStr | IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis |
title_full_unstemmed | IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis |
title_short | IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis |
title_sort | il-6 receptor blockade increases circulating adiponectin levels in people with obesity: an explanatory analysis |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911215/ https://www.ncbi.nlm.nih.gov/pubmed/33572989 http://dx.doi.org/10.3390/metabo11020079 |
work_keys_str_mv | AT wueeststephan il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis AT seeligeleonora il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis AT timperkatharina il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis AT lyngbaekmarkp il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis AT karstoftkristian il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis AT donathmarcy il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis AT ellingsgaardhelga il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis AT konraddaniel il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis |